Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30707192 | 1.00 | HTR2A (0.41) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL30474183 | 0.82 | IDO1 (0.35) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL16998685 | 0.82 | IDO1 (0.35) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL8237259 | 0.79 | HTR2A (0.42) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL16752294 | 0.79 | KMT2A (0.48) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL10019194 | 0.78 | KCNH2 (0.39) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL233314 | 0.78 | TAAR1 (0.41) | HTR2AALDH1A1MAPTPOLBTAAR1 | |
| SCHEMBL2735698 | 0.77 | HTR2A (0.41) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL6111929 | 0.77 | PNMT (0.48) | HTR2ASLC6A4KCNH2ALDH1A1MAPT | |
| SCHEMBL320779 | 0.77 | HTR2A (0.41) | HTR2ASLC6A4KCNH2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9499521-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-16 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168128-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | HTR2A 4383/4885SLC6A4 2491/4885KCNH2 4731/4885 |
| US-20160304498-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | HTR2A 4383/4885SLC6A4 2491/4885KCNH2 4731/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | HTR2A 1742/4885SLC6A4 2827/4885KCNH2 426/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | HTR2A 1326/4885SLC6A4 1317/4885KCNH2 4083/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | HTR2A 1326/4885SLC6A4 1317/4885KCNH2 4083/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | HTR2A 1326/4885SLC6A4 1317/4885KCNH2 4083/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2A 4594/4885SLC6A4 4681/4885KCNH2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.